Literature DB >> 18658087

Suppression of injury-induced conjunctiva scarring by peroxisome proliferator-activated receptor gamma gene transfer in mice.

Osamu Yamanaka1, Ken-ichi Miyazaki, Ai Kitano, Shizuya Saika, Yuji Nakajima, Kazuo Ikeda.   

Abstract

PURPOSE: To examine the effects of introduction of the adenoviral peroxisome proliferator-activated receptor (PPAR)-gamma gene on postinjury conjunctival scarring in mice. Its effects on fibrogenic reaction of cultured human subconjunctival fibroblasts (hSCFs) were also evaluated.
METHODS: The effects of PPARgamma gene introduction on expression of type I collagen, fibronectin, and connective tissue growth factor (CTGF) in hSCFs were examined. A circumferential incision was made in the equatorial conjunctiva of the right eye of generally anesthetized adult C57BL/6 mice (n = 72). PPARgamma cDNA-expressing adenoviral vector was topically applied; the control eye received nonfunctioning adenoviral vector. At 2, 5, 7, and 14 days (each, n = 18), the eyes were processed for histologic or immunohistochemical examination to evaluate tissue scarring. Expression of type I collagen and growth factors was evaluated by real-time reverse transcription-polymerase chain reaction in 32 eyes from control and treatment groups.
RESULTS: PPARgamma overexpression suppressed type I collagen, fibronectin, and CTGF in cultured hSCFs at the mRNA or protein level. In vivo experiments showed that PPARgamma gene introduction suppressed monocyte/macrophage invasion, generation of myofibroblasts, and mRNA upregulation of cytokines/growth factors and collagen Ialpha2 chain (Col 1A2) in healing conjunctiva.
CONCLUSIONS: PPARgamma gene transfer suppresses the fibrogenic reaction in hSCFs as well as the injury-induced scarring of conjunctival tissue in mice, suggesting the effectiveness of this strategy in preventing excess scarring after filtration surgery. The mechanism may include suppression of activation of fibroblasts and reduction of macrophage invasion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18658087     DOI: 10.1167/iovs.08-2282

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

Review 1.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 2.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

3.  Rosiglitazone attenuates activation of human Tenon's fibroblasts induced by transforming growth factor-β1.

Authors:  Fang Fan; Yuehua Li; Xuanchu Duan; Tantai Zhao; Dongning Pan; Huihui Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-04       Impact factor: 3.117

4.  Pioglitazone inhibits TGFβ induced keratocyte transformation to myofibroblast and extracellular matrix production.

Authors:  Hong-Wei Pan; Jin-Tang Xu; Jian-Su Chen
Journal:  Mol Biol Rep       Date:  2010-12-03       Impact factor: 2.316

Review 5.  Corneal gene therapy: basic science and translational perspective.

Authors:  Rajiv R Mohan; Jason T Rodier; Ajay Sharma
Journal:  Ocul Surf       Date:  2013-02-13       Impact factor: 5.033

6.  Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.

Authors:  Naxin Guo; Collynn F Woeller; Steven E Feldon; Richard P Phipps
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

Review 7.  Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.

Authors:  Su Zhang; Hongwei Gu; Nan Hu
Journal:  J Ophthalmol       Date:  2015-06-04       Impact factor: 1.909

8.  Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.

Authors:  Hongwei Pan; Jiansu Chen; Jintang Xu; Miaojiao Chen; Rong Ma
Journal:  Mol Vis       Date:  2009-11-10       Impact factor: 2.367

9.  Sonic hedgehog: its expression in a healing cornea and its role in neovascularization.

Authors:  Kyoko Fujita; Takeshi Miyamoto; Shizuya Saika
Journal:  Mol Vis       Date:  2009-05-18       Impact factor: 2.367

10.  Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo.

Authors:  David R Brigstock
Journal:  J Cell Commun Signal       Date:  2009-03-18       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.